Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).  Preliminary analysis demonstrates that the trial has met its primary endpoint.

FREEDOM-M was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness.  The study enrolled 349 patients who were not receiving any approved PAH medication, with the population for the primary analysis consisting of the 228 patients who had access to the 0.25 mg tablet at randomization.  These patients were administered oral treprostinil or placebo twice daily, with the doses titrated to effect over the course of the 12-week trial.  The majority of patients were in World Health Organization (WHO) Functional Class II (~33%) and Class III (~66%) of varied etiologies, including idiopathic or familial PAH (~75%), collagen vascular disease associated PAH (~19%), and PAH associated with HIV or other associated conditions (~6%).  The patients’ mean baseline six-minute walk distance (6MWD) was approximately 330 meters.

The primary efficacy endpoint of the trial was the change in 6MWD at 12 weeks for the 228 patients.  Preliminary analysis of the FREEDOM-M results demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 23 meters (p=0.0125, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial’s pre-specified statistical analysis plan) as compared to patients receiving placebo.  The median change from baseline was 25 meters for oral treprost
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Calif. , May 22, 2013  Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following ... Conference , Presentation date: Wednesday May 29, 2013 ... Jefferies 2013 Global Healthcare Conference , Presentation date: Wednesday ... A live webcast and ...
(Date:5/22/2013)...  Flagship Ventures, a leading venture capital and ... today announced the appointment of Stephane ... this role, Mr. Bancel will provide strategic counsel ... addition to working closely with companies in the ... and Chief Executive Officer of Moderna Therapeutics, a ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... ALTO, Calif., Nov. 3, 2011 Telik, Inc. (Nasdaq: ... million, or $0.05 per share, for the third quarter ended ... million, or $0.09 per share, for the comparable period in ... total operating costs and expenses were $2.9 million, compared with $4.7 ...
... Aoxing Pharmaceutical (NYSE Amex: AXN ) ... research, development, manufacturing and distribution of narcotic, pain-management, ... operating subsidiary in China, Hebei Aoxing Pharmaceutical Group ... million RMB (approximately $315,000) from the Industry and ...
Cached Medicine Technology:Telik Announces Third Quarter 2011 Financial Results 2Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China 2Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China 3
(Date:5/22/2013)... challenges previous research that suggests umpire discrimination exists ... collaboration between researchers at U-M and the universities ... controversial argument over whether MLB umpires discriminate by ... same race. It found little statistical evidence to ... of sport management at the U-M School of ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Over the next two ... States is expected to more than double, topping more ... The main factor driving the increase: an aging ... and the American Stroke Association, was published May 22 ... absolutely strain the health care system," Dr. Bruce Ovbiagele, ...
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in Sleepy ... Center for individuals who would like to be screened ... is the deadliest form of cancer for both men and ... from lung cancer than from breast, colon and prostate cancer ... survival rates. It is well established that routine mammography ...
(Date:5/22/2013)... RI (PRWEB) May 22, 2013 Hurricane ... weatherproofing your home. That’s why Amica Insurance ... coverages for the upcoming hurricane season. , “An important ... said Bryan Cook, a senior assistant vice president at ... needs is before the threat of a storm.” , ...
Breaking Medicine News(10 mins):Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2
... than 40 years, Earth observing satellites have delivered valuable ... understanding and improved management of the Earth and its ... decision-makers are faced with responding to environmental change, managing ... security issues. , In order to address these needs, ...
... 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (Amex: ... Company,), a,manufacturer, marketer and distributor of pharmaceutical, medicinal ... has engaged MSPC,Certified Public Accountants and Advisors LLP ... 2008. The Company terminated its,contract with Sherb & ...
... Storage Systems, Software And Services To Deliver ... Higher Performance and Greater Reliability, ... EMC ),the world leader in information infrastructure solutions, announced ... headquarters,of Boston Health Care for the Homeless Program (BHCHP), ...
... panel of judges to select winning online ... Microsoft Corp. has,increased award funding from ... 200 proposals from leading academic and research ... http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO ), Proposals represent a ...
... Contest and More than ... $10,000 in Cash and Prizes, HOFFMAN ESTATES, Ill., May ... grand prize winner of the,annual "New Day Your Way" contest, which is ... their fitness goals,in 2008. During the 12-week contest, Kmart provided more than ...
... German . , A measuring procedure ... investigate in some detail the behaviour of magnetic nanoparticles ... (with a size of some few to several hundred ... The particles serve as a carrier for drugs: "loaded" ...
Cached Medicine News:Health News:European conference addresses increasing demand for EO data 2Health News:China Sky One Medical, Inc. Engages Moore Stephens as New Independent Auditor 2Health News:China Sky One Medical, Inc. Engages Moore Stephens as New Independent Auditor 3Health News:EMC Strengthens Information Infrastructure for Boston Health Care for the Homeless Program 2Health News:EMC Strengthens Information Infrastructure for Boston Health Care for the Homeless Program 3Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 2Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 3Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 4Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 5Health News:The Weight Is Over: Five Winners Lose 194 Pounds as Kmart Encourages 24,000 Americans to Achieve Healthier Lifestyle 2Health News:Magnetic nanoparticles: Suitable for cancer therapy? 2
... Wampole EBV ELISA test panel ... assays for the determination of ... for Viral Capsid Antigen (VCA), ... Antigen (EBNA). Most Wampole EBV ...
Herpes Simplex Virus Group IgG....
Cytomegalovirus IgG ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Medicine Products: